Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. As a pioneer in biotechnology since 1980, Amgen uses living cells to make biologic medicines addressing cardiovascular metabolic conditions, oncology, inflammation, rare diseases, and bone health, operating in approximately 100 countries worldwide.
APIs
Amgen Website
Amgen discovers, develops, manufactures, and delivers innovative biologic medicines for patients with serious illnesses. The company does not currently publish a public develope...
Features
Pioneering use of living cells and human genetic data combined with AI and generative biology to discover novel biologic medicines.
Cancer medicines targeting solid tumors and hematologic malignancies including innovative BiTE and antibody therapies.
Medicines addressing heart disease, high cholesterol (Lp(a)), obesity, and obesity-related metabolic conditions.
Treatments for inflammatory conditions including chronic rhinosinusitis with nasal polyps, asthma, and other immune-mediated diseases.
Therapies for rare conditions including IgG4-related disease (IgG4-RD), generalized myasthenia gravis, and other orphan indications.
Medicines for osteoporosis, bone metastases, and other bone health conditions including PROLIA and XGEVA.
High-quality biosimilar medicines providing more affordable alternatives to reference biologic therapies across multiple therapeutic areas.
Application of artificial intelligence, generative biology, and advanced data science to accelerate drug discovery and clinical trial optimization.
Use Cases
Providing oncology medicines for patients with solid tumors and blood cancers through innovative biologic and targeted therapies.
Reducing cardiovascular risk with medicines targeting LDL cholesterol, Lp(a), and other cardiovascular risk factors.
Managing chronic inflammatory conditions with targeted biologic therapies for patients with severe unmet medical needs.
Delivering life-changing therapies to patients with rare and ultra-rare diseases where few or no other treatments exist.
Improving patient access to biologic therapies through high-quality, lower-cost biosimilar medicines.
Addressing obesity and obesity-related conditions with novel medicines targeting metabolic pathways.
Integrations
Patient support program providing financial assistance, insurance navigation, and access services for Amgen medicines.
Global clinical research network conducting Phase I through Phase III trials across therapeutic areas with AI-optimized trial design.
Portfolio of biosimilar medicines offered through partnerships with healthcare systems globally to improve treatment access.